Stock analysts at StockNews.com began coverage on shares of Veradigm (NASDAQ:MDRX - Get Free Report) in a research report issued on Wednesday. The firm set a "hold" rating on the software maker's stock.
Separately, Stephens raised their target price on Veradigm from $7.00 to $13.00 and gave the company an "equal weight" rating in a research report on Friday, January 31st.
Get Our Latest Report on MDRX
Veradigm Stock Performance
Shares of MDRX traded down $0.30 on Wednesday, reaching $4.00. 577,731 shares of the company's stock traded hands, compared to its average volume of 467,819. The stock's 50 day simple moving average is $5.16 and its two-hundred day simple moving average is $8.10. Veradigm has a 52-week low of $3.90 and a 52-week high of $11.80.
Veradigm Company Profile
(
Get Free Report)
Veradigm Inc, a healthcare technology company, provides information technology solutions and services to healthcare organizations in the United States, Canada, and internationally. It offers electronic health records (EHR), information connectivity, private cloud hosting, outsourcing, analytics, patient access, and population health management solutions.
See Also
Before you consider Veradigm, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Veradigm wasn't on the list.
While Veradigm currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
